Condition: Atopic Dermatitis (AD) · Sponsor: Bluefin Biomedicine, Inc.
This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.
This description comes directly from the study's public registry record.
Rob Eichelkraut · +1-214-728-6505 · Reichelkraut@bluefinbiomed.com
Always discuss trial participation with your own doctor first.
| Mountain West Derm - Blackhart PLLC dba Skin Cancer and Dermatology Institute | Phoenix, Arizona, United States | Recruiting |
| Skin Cancer and Dermatology Institute | Phoenix, Arizona, United States | Recruiting |
| T. Joseph Raoof Md, Inc | Encino, California, United States | Recruiting |
| Marvel Clinical Research | Huntington Beach, California, United States | Recruiting |
| Antelope Valley Clinical Trials | Lancaster, California, United States | Recruiting |
| Probity Medical Research | Los Angeles, California, United States | Recruiting |
| NorCal Clinical Research | Rocklin, California, United States | Recruiting |
| Focus Clinical Research, LLC -S | West Hills, California, United States | Recruiting |
| Skin Care Research | Boca Raton, Florida, United States | Recruiting |
| Florida Academic Dermatology Center Res and Edu, LLC | Coral Gables, Florida, United States | Recruiting |
| Center for Skin Science and Innovation | Fort Lauderdale, Florida, United States | Recruiting |
| Gsi Clinical Research | Margate, Florida, United States | Recruiting |
+ 76 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07105488